Buy or sell Caribou Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Caribou Biosciences Stock

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular.

Founded

2011

Headquarters

Berkeley CA, US

Total Funding

$44.5M

About Caribou Biosciences Stock

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.

Funding History

October 2014$2.9M
March 2015$11.5M
May 2016$30.0M

Management

Co-Founder

Jennifer A. Doudna

Co-founder

James Berger

Group Leader, Agriculture and Industrial Biotechnology

Vonnie Estes

Chief Legal Officer, Corporate Secretary

Barbara McClung

Co-Founder , President & CEO

Rachel E. Haurwitz

Vice President of Informatics

Chris Fuller

Co-founder

Martin Jinek

Chief Scientific Officer

Andy May

Vice President of Platform Re

Scott Gradia

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Caribou Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo